Enalapril (marketed as Vasotec in the US, Enaladex and Renitec in some other countries, and Enacard for veterinary use[1]:142-143) is an angiotensin-converting-enzyme (ACE) inhibitor used in the treatment of hypertension, diabetic nephropathy, and some types of chronic heart failure.

Starting at
| (2S)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylic acid |
| Trade names | Vasotec, Renitec |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a686022 |
| Pregnancy category |
C,D |
| Legal status | ℞ (Prescription only) |
| Routes of administration |
by mouth |
| Bioavailability | 60% (oral) |
| Metabolism | hepatic (to enalaprilat) |
| Biological half-life | 11 hours (enalaprilat) |
| Excretion | renal |
| CAS Number | 75847-73-3 |
| ATC code | C09AA02 |
| PubChem | CID: 5388962 |
| IUPHAR/BPS | 6322 |
| DrugBank | DB00584 |
| ChemSpider | 4534998 |
| UNII | 69PN84IO1A |
| KEGG | D07892 |
| ChEBI | CHEBI:4784 |
| ChEMBL | CHEMBL578 |
| Formula | C20H28N2O5 |
| Molecular mass | 376.447 g/mol |
| SMILES[show] | |
| InChI[show] | |
| Melting point | 143 to 144.5 °C (289.4 to 292.1 °F) |